Study of BMN-270 at a dose of 6e13vg/kg in patients with severe haemophilia A

Trial Profile

Study of BMN-270 at a dose of 6e13vg/kg in patients with severe haemophilia A

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Valoctocogene-roxaparvovec (Primary)
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Dec 2017 According to a BioMarin Pharmaceutical media release, this trial will enroll its first patient this month.
    • 26 Oct 2017 According to a BioMarin Pharmaceutical media release, Clinical Trial Applications have also been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for study protocol.
    • 26 Oct 2017 According to a BioMarin Pharmaceutical media release, the company expects complete enrollment of the last patient by the end of 2018 and provide top-line Phase 3 data by the end of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top